Artwork

Contenuto fornito da Swisspreneur. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Swisspreneur o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

EP #364 - Reto Naef: Disruptive Therapies for Aging Diseases

54:10
 
Condividi
 

Manage episode 390001850 series 1259851
Contenuto fornito da Swisspreneur. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Swisspreneur o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Timestamps:

13:03 - The birth of TOPADUR

18:07 - Leaving the cushy life for entrepreneurship

23:26 - TOPADUR’s drug development

30:36 - Financing pharma

38:08 - Sparks IPO Academy

About Reto Naef:

Reto Naef is the founder and former CEO of TOPADUR PHARMA AG, a biopharmaceutical company developing disruptive therapies for aging diseases. He holds a PhD in Chemistry from ETH and an MBA from UZH and previously worked for pharma companies like Sandoz and Novartis before starting TOPADUR in 2015.

TOPADUR develops dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on this key invention, they’ve built a portfolio of drug candidates to treat aging-related diseases like chronic wounds, skin fibrosis, age-related macular degeneration, colorectal cancer, hair loss and skin aging.

TOPADUR recently participated in the Sparks IPO Academy as part of their journey towards going public. They estimate that an IPO will be possible around early 2025, provided that they successfully bring all the drugs in their portfolio to market. Reto decided to step down from his operative role in 2023.

Don’t forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there’s no excuse for missing out on live shows, weekly giveaways or founders' dinners.

  continue reading

402 episodi

Artwork
iconCondividi
 
Manage episode 390001850 series 1259851
Contenuto fornito da Swisspreneur. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Swisspreneur o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Timestamps:

13:03 - The birth of TOPADUR

18:07 - Leaving the cushy life for entrepreneurship

23:26 - TOPADUR’s drug development

30:36 - Financing pharma

38:08 - Sparks IPO Academy

About Reto Naef:

Reto Naef is the founder and former CEO of TOPADUR PHARMA AG, a biopharmaceutical company developing disruptive therapies for aging diseases. He holds a PhD in Chemistry from ETH and an MBA from UZH and previously worked for pharma companies like Sandoz and Novartis before starting TOPADUR in 2015.

TOPADUR develops dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on this key invention, they’ve built a portfolio of drug candidates to treat aging-related diseases like chronic wounds, skin fibrosis, age-related macular degeneration, colorectal cancer, hair loss and skin aging.

TOPADUR recently participated in the Sparks IPO Academy as part of their journey towards going public. They estimate that an IPO will be possible around early 2025, provided that they successfully bring all the drugs in their portfolio to market. Reto decided to step down from his operative role in 2023.

Don’t forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there’s no excuse for missing out on live shows, weekly giveaways or founders' dinners.

  continue reading

402 episodi

Усі епізоди

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida